These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 31726765)

  • 21. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
    Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
    J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.
    Wakisaka M; Nakamura K; Nakano T; Kitazono T
    J Endocr Soc; 2021 Aug; 5(8):bvab083. PubMed ID: 34195526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
    Nirengi S; Peres Valgas da Silva C; Stanford KI
    Curr Opin Pharmacol; 2020 Oct; 54():82-90. PubMed ID: 32980777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
    Wang XX; Levi J; Luo Y; Myakala K; Herman-Edelstein M; Qiu L; Wang D; Peng Y; Grenz A; Lucia S; Dobrinskikh E; D'Agati VD; Koepsell H; Kopp JB; Rosenberg AZ; Levi M
    J Biol Chem; 2017 Mar; 292(13):5335-5348. PubMed ID: 28196866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
    Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
    Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
    Packer M
    Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
    Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
    Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
    Barutta F; Bernardi S; Gargiulo G; Durazzo M; Gruden G
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3171. PubMed ID: 30997935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.
    Wakisaka M; Nagao T
    Glycobiology; 2017 Aug; 27(8):691-695. PubMed ID: 28535208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
    Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
    [No Abstract]   [Full Text] [Related]  

  • 38. Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
    Li N; Zhou H
    Curr Pharm Des; 2022; 28(26):2131-2139. PubMed ID: 35718973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
    Eur J Heart Fail; 2021 Aug; 23(8):1260-1275. PubMed ID: 34184823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.